Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Lutathera® Plus Octreotide LAR 30 mg	32	147
Total, all-cause mortality	Octreotide LAR 60 mg (Control Arm)	14	73
Total, all-cause mortality	Crossover Lutathera	3	29
Total, all-cause mortality	Re-Treatment Lutathera	0	8
Total, other adverse events	Lutathera® Plus Octreotide LAR 30 mg	129	147
Total, other adverse events	Octreotide LAR 60 mg (Control Arm)	65	73
Total, other adverse events	Crossover Lutathera	22	29
Total, other adverse events	Re-Treatment Lutathera	6	8
Total, serious adverse events	Lutathera® Plus Octreotide LAR 30 mg	30	147
Total, serious adverse events	Octreotide LAR 60 mg (Control Arm)	15	73
Total, serious adverse events	Crossover Lutathera	2	29
Total, serious adverse events	Re-Treatment Lutathera	0	8

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03972488/event-totals